ABBV Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

255.820

Open

253.250

VWAP

253.09

Vol

7.58M

Mkt Cap

446.54B

Low

250.700

Amount

1.92B

EV/EBITDA(TTM)

17.07

Total Shares

1.77B

EV

513.42B

EV/OCF(TTM)

24.19

P/S(TTM)

7.19

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

Show More

Events Timeline

(ET)

2026-07-07

16:30:00

Nasdaq Retreats Amid Chip Sector Declines

2026-07-06 (ET)

2026-07-06

20:00:00

Large-Cap Growth Stocks Shine, Crinetics Pharmaceuticals Up 100%

2026-07-06

16:30:00

AbbVie 2026 Adjusted EPS Guidance Range $13.91 - $14.11

2026-07-06

16:30:00

AbbVie Sees Q2 Adjusted EPS Guidance of $3.57-$3.61

2026-07-06

16:30:00

AbbVie Expects $291 Million Impact on Q2 2026 EPS

2026-07-06

14:00:00

AbbVie’s TEPKINLY Approved by EU for Relapsed Lymphoma Treatment

2026-07-06

14:00:00

Genmab Receives Approval for TEPKINLY in Combination Therapy for Relapsed Follicular Lymphoma

2026-06-30 (ET)

2026-06-30

11:00:00

U.S. Lawmakers Investigate Merck and AbbVie Clinical Trials in China

News

PRnewswire

07-06PRnewswire

PinnedTEPKINLY Receives EU Approval for Relapsed Lymphoma Treatment

PRnewswire

07-06PRnewswire

PinnedAbbVie Receives EU Approval for TEPKINLY in Follicular Lymphoma Treatment

Yahoo Finance

07-08Yahoo Finance

Major US Biopharmaceutical Companies Expected to Underperform in H2

Fool

Novo Nordisk Faces Challenges but Optimistic Outlook Ahead

Fool

U.S. Healthcare Spending Reaches $5.7 Trillion Amid Growth Trends

NASDAQ.COM

07-07NASDAQ.COM

Eli Lilly and Intuitive Surgical's Growth Potential

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

HSBC

Buy

maintain

$275 -> $300

AI Analysis

2026-07-06

New

Reason

HSBC

Price Target

$275 -> $300

AI Analysis

2026-07-06

New

maintain

Buy

Reason

HSBC raised the firm's price target on AbbVie to $300 from $275 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."

Cantor Fitzgerald

NULL

to

Overweight

maintain

$240 -> $265

2026-07-06

New

Reason

Cantor Fitzgerald

Price Target

$240 -> $265

2026-07-06

New

maintain

NULL

to

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on AbbVie to $265 from $240 and keeps an Overweight rating on the shares. Large-cap biopharmas are expected to report broadly strong Q2 results that support further FY26 top-line guidance raises, though sustainability of recent momentum remains in question as the sector is still viewed as a rotation beneficiary from AI names rather than being purely fundamentals-driven, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abbvie Inc (ABBV.N) is 18.35, compared to its 5-year average forward P/E of 13.72. For a more detailed relative valuation and DCF analysis to assess Abbvie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

13.72

Current PE

18.35

Overvalued PE

16.37

Undervalued PE

11.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

12.98

Current EV/EBITDA

16.34

Overvalued EV/EBITDA

16.01

Undervalued EV/EBITDA

9.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.04

Current PS

6.19

Overvalued PS

5.79

Undervalued PS

4.30

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks low shorts under 50 k

Intellectia · 492 candidates

Region: USShort Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

JPMorgan Chase & Co

882.60B

Abbvie Inc

449.31B

HSBC Holdings PLC

326.39B

Amgen Inc

194.59B

UBS Group AG

162.22B

Charles Schwab Corp

157.69B

stocks with zero short shares available

Intellectia · 492 candidates

Region: USShort Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

JPMorgan Chase & Co

882.60B

Abbvie Inc

449.31B

HSBC Holdings PLC

326.39B

Amgen Inc

194.59B

UBS Group AG

162.22B

Charles Schwab Corp

157.69B

best quantum computer companies

Intellectia · 868 candidates

Market Cap Category: small, mid, large, megaAnalyst Consensus: Strong Buy, Moderate BuyRelative Vol: >= 1.50Target Price Upside Potential: AbovePrice, MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

NVIDIA Corp

5.10T

Apple Inc

4.38T

Broadcom Inc

1.96T

Walmart Inc

932.53B

JPMorgan Chase & Co

871.43B

Visa Inc

619.95B

Intellectia · 9 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, PharmaceuticalsPrice: >= $-100.00Volume: >= -100Themes: Medical Instruments & Supplies, Genomics, Cancer Research, BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Ema 20: >= -100Ema 60: >= -100Weekly Average Dollar Volume: >= -100

Ticker

Name

Market Cap$

Johnson & Johnson

570.51B

AbbVie Inc

398.27B

Merck & Co Inc

295.39B

Amgen Inc

185.96B

Vertex Pharmaceuticals Inc

113.14B

Biogen Inc

29.39B

Mega Cap Stocks Bullish for a Month

Intellectia · 22 candidates

Market Cap Category: megaMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 50One Month Predict Return: >= 0.0%Macd: bullish

Ticker

Name

Market Cap$

Micron Technology Inc

1.22T

Cisco Systems Inc

498.59B

International Business Machines Corp

287.26B

Advanced Micro Devices Inc

884.63B

Oracle Corp

662.44B

KLA Corp

277.60B

Intellectia · 21 candidates

Market Cap: >= 500.00MRegion: USVolume: >= 500,000Analyst Consensus: Strong Buy, Moderate Buy, HoldRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

Eli Lilly and Co

1000.00B

Lam Research Corp

403.53B

AbbVie Inc

376.54B

General Electric Co

328.12B

Corning Inc

168.83B

General Dynamics Corp

93.20B

stocks up in a down market

Intellectia · 87 candidates

Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Is Index Component: GSPCEma 20: >= 0Macd: bullish

Ticker

Name

Market Cap$

Apple Inc

4.39T

Walmart Inc

1.07T

Exxon Mobil Corp

673.76B

Visa Inc

625.00B

Costco Wholesale Corp

485.50B

Cisco Systems Inc

455.74B

which megacap surged max yesterday

Intellectia · 64 candidates

Region: USMarket Cap Category: mega

Ticker

Name

Market Cap$

UnitedHealth Group Inc

359.98B

Philip Morris International Inc

291.34B

Netflix Inc

369.12B

AbbVie Inc

367.25B

Eli Lilly and Co

932.20B

Costco Wholesale Corp

453.36B

what stock earnings next week

Intellectia · 133 candidates

Market Cap: >= 10.00BPrice: >= $10.00Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Alphabet Inc

4.09T

Microsoft Corp

3.09T

Amazon.com Inc

2.74T

Meta Platforms Inc

1.67T

Visa Inc

588.73B

AbbVie Inc

355.43B

Intellectia · 1131 candidates

Market Cap: >= 2.00BPrice: >= $5.00List Exchange: XNYSMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Berkshire Hathaway Inc

1.02T

Berkshire Hathaway Inc

1.02T

Walmart Inc

995.12B

Eli Lilly and Co

854.11B

JPMorgan Chase & Co

831.35B

Whales Holding ABBV

Mubadala Investment Company PJSC

Pallas Capital Advisors LLC

TCW Group, Inc.

Epoch Investment Partners, Inc.

Bellevue Asset Management AG

Allianz Global Investors U.S. LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abbvie Inc (ABBV) stock price today?

The current price of ABBV is 252.74 USD — it has decreased -0.75

What is Abbvie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abbvie Inc (ABBV)'s revenue for the last quarter?

Abbvie Inc revenue for the last quarter amounts to 15.00B USD, increased 12.43

What is Abbvie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

Abbvie Inc. EPS for the last quarter amounts to 0.39 USD, decreased -45.83

How many employees does Abbvie Inc (ABBV). have?

Abbvie Inc (ABBV) has 57000 emplpoyees as of July 09 2026.

What is Abbvie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 446.54B USD.